ClinicalTrials.Veeva

Find clinical trials for Chronic Lymphocytic Leukemia in Sevilla, AN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Chronic Lymphocytic Leukemia
Leukemia
Lymphoid Leukemia
Lymphoma
B-Cell Lymphoma
Mantle-Cell Lymphoma
Non-Hodgkin Lymphoma

Chronic Lymphocytic Leukemia trials near Sevilla, AN, ESP:

A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-313)

The purpose of this study is to compare the efficacy and safety of pirtobrutinib (LOXO-305; Arm A) compared to BR (Arm B) in patients with CLL/SLL wh...

Active, not recruiting
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Pirtobrutinib
Drug: Bendamustine

Phase 3

Loxo Oncology
Loxo Oncology

Sevilla, Spain and 145 other locations

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN-CLL-314)

The purpose of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL. Participants...

Enrolling
Leukemia, B-cell
Small Lymphocytic Lymphoma
Drug: Pirtobrutinib
Drug: Ibrutinib

Phase 3

Loxo Oncology
Loxo Oncology

Sevilla, Spain and 179 other locations

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome (EPCORE™ CLL-1)

study includes patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL)/small lymphocytic lympho...

Enrolling
Small Lymphocytic Lymphoma
Relapsed/Refractory Chronic Lymphocytic Leukemia
Drug: Venetoclax
Biological: Epcoritamab

Phase 1, Phase 2

Genmab
Genmab

Sevilla, Spain and 74 other locations

A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (GLOW)

The purpose of this study is to assess progression-free survival (PFS) from treatment with ibrutinib plus venetoclax (I+VEN) compared with obinutuzum...

Active, not recruiting
Leukemia, Lymphocytic, Chronic, B-Cell
Drug: Obinutuzumab
Drug: Venetoclax

Phase 3

Janssen (J&J Innovative Medicine)

Sevilla, Spain and 85 other locations

A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) (topMIND)

The purpose of this single-arm, open-label, Phase 1b/2a, multicenter basket study is to evaluate whether tafasitamab and parsaclisib can be safely co...

Active, not recruiting
Chronic Lymphocytic Leukemia
Non Hodgkin Lymphoma
Drug: tafasitamab
Drug: parsaclisib

Phase 1, Phase 2

Incyte
Incyte

Sevilla, Spain and 49 other locations

Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-321)

This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL)...

Active, not recruiting
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Idelalisib
Drug: Bendamustine

Phase 3

Loxo Oncology
Loxo Oncology

Sevilla, Spain and 231 other locations

A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (BRUIN CLL-322)

The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm...

Enrolling
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Venetoclax
Drug: Rituximab

Phase 3

Loxo Oncology
Loxo Oncology

Sevilla, Spain and 196 other locations

A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation (CRISTALLO)

This study will evaluate the efficacy and safety of venetoclax and obinutuzumab (VEN + G) compared with fludarabine + cyclophosphamide + rituximab or...

Active, not recruiting
Chronic Lymphocytic Leukemia (CLL)
Drug: Fludarabine
Drug: Cyclophosphamide

Phase 3

Roche
Roche

Sevilla, Spain and 47 other locations

Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL

A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with AML, ALL (with...

Enrolling
Acute Mixed-Phenotype Leukemia
Small Lymphocytic Lymphoma
Drug: BMF-219

Phase 1

Biomea Fusion

Sevilla, Spain and 40 other locations

Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

venetoclax versus obinutuzumab + chlorambucil in participants with chronic lymphocytic leukemia (CLL) and coexisting medic...

Active, not recruiting
Lymphocytic Leukemia, Chronic
Drug: Venetoclax
Drug: Obinutuzumab

Phase 3

Roche
Roche

Sevilla, Spain and 136 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems